"Antibodies, Bispecific" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
| Descriptor ID |
D018033
|
| MeSH Number(s) |
D12.776.124.486.485.114.125 D12.776.124.790.651.114.134 D12.776.377.715.548.114.134
|
| Concept/Terms |
Antibodies, Bispecific- Antibodies, Bispecific
- Bispecific Antibodies
- Bifunctional Antibodies
- Antibodies, Bifunctional
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Bispecific".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Bispecific".
This graph shows the total number of publications written about "Antibodies, Bispecific" by people in this website by year, and whether "Antibodies, Bispecific" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 5 | 0 | 5 |
| 2022 | 1 | 0 | 1 |
| 2023 | 4 | 0 | 4 |
| 2024 | 3 | 3 | 6 |
| 2025 | 4 | 2 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Bispecific" by people in Profiles.
-
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncol. 2025 Jul; 21(16):2007-2016.
-
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response. Blood. 2025 May 22; 145(21):2460-2472.
-
Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmic Surg Lasers Imaging Retina. 2025 Aug; 56(8):468-477.
-
Early Outcomes After Initiation of Faricimab in Patients With Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2025 Aug; 56(8):478-486.
-
Bispecific antibody targeting shared indel-derived neoantigen of APC. Front Immunol. 2025; 16:1574958.
-
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. Cancer. 2025 Feb 01; 131(3):e35738.
-
Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study. Eye (Lond). 2025 Apr; 39(6):1099-1106.
-
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27; 392(9):875-891.
-
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024 Dec 05; 144(23):2375-2388.
-
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024 07 25; 391(4):320-333.